A new monocyte chemotactic protein-1/chemokine cc motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice

Journal of the American College of Cardiology

Volumn 56, Issue 22, 2010, Pages 1847-1857

  Liehn, Elisa A ^a,b   Piccinini, Anna Maria ^c   Koenen, Rory R ^a,d   Soehnlein, Oliver ^a   Adage, Tiziana ^c   Fatu, Roxana ^a   Curaj, Adelina ^a,e   Popescu, Alexandra ^a,e   Zernecke, Alma ^a,f   Kungl, Andreas J ^c   Weber, Christian ^a,b,d  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c ProtAffin Biotechnologie AG   (Austria)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^f UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CARDIOVASCULAR AGENT; CHEMOKINE RECEPTOR CCR2; COLLAGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PA 508; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CALCIUM TRANSPORT; CAROTID ARTERY; CELL MIGRATION; CELL STRUCTURE; CELL TYPE; CONTROLLED STUDY; DRUG HALF LIFE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HYPERLIPIDEMIA; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; MONONUCLEAR CELL; MOUSE; MYOFIBROBLAST; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REPERFUSION INJURY; SEQUENCE ALIGNMENT; SMOOTH MUSCLE FIBER; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

ANIMALS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MYOCARDIAL REPERFUSION INJURY; NEOINTIMA;

EID: 78449282952     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.066     Document Type: Article

References (44)

1. W.M. Blankesteijn, E. Creemers, E. Lutgens, J.P. Cleutjens, M.J. Daemen, and J.F. Smits Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice Acta Physiol Scand 173 2001 75 82
2. L. Lu, J.Q. Zhang, F.J. Ramires, and Y. Sun Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue Biochem Biophys Res Commun 320 2004 907 913
3. G. Ren, O. Dewald, and N.G. Frangogiannis Inflammatory mechanisms in myocardial infarction Curr Drug Targets Inflamm Allergy 2 2003 242 256
4. F. Yang, Y.H. Liu, X.P. Yang, J. Xu, A. Kapke, and O.A. Carretero Myocardial infarction and cardiac remodelling in mice Exp Physiol 87 2002 547 555
5. A. Zernecke, E. Shagdarsuren, and C. Weber Chemokines in atherosclerosis: an update Arterioscler Thromb Vasc Biol 28 2008 1897 1908
6. C. Weber, A. Zernecke, and P. Libby The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models Nat Rev Immunol 8 2008 802 815
7. N.G. Frangogiannis Chemokines in ischemia and reperfusion Thromb Haemost 97 2007 738 747
8. N.G. Frangogiannis, C.W. Smith, and M.L. Entman The inflammatory response in myocardial infarction Cardiovasc Res 53 2002 31 47
9. A.E. Proudfoot, C.A. Power, and A.J. Hoogewerf Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist J Biol Chem 271 1996 2599 2603
10. Z. Johnson, M.H. Kosco-Vilbois, and S. Herren Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system J Immunol 173 2004 5776 5785
11. T.M. Handel, Z. Johnson, and D.H. Rodrigues An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo J Leukoc Biol 84 2008 1101 1108
12. L. Gu, S.C. Tseng, and B.J. Rollins Monocyte chemoattractant protein-1 Chem Immunol 72 1999 7 29
13. K.S. Weber, P.J. Nelson, H.J. Grone, and C. Weber Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium Arterioscler Thromb Vasc Biol 19 1999 2085 2093
14. N. Sakai, T. Wada, and K. Furuichi MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes J Leukoc Biol 79 2006 555 563
15. K. Kaikita, T. Hayasaki, T. Okuma, W.A. Kuziel, H. Ogawa, and M. Takeya Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction Am J Pathol 165 2004 439 447
16. M. Usui, K. Egashira, and K. Ohtani Anti-MCP-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys FASEB J 16 2002 1838 1840
17. A. Schober, A. Zernecke, and E.A. Liehn Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets Circ Res 95 2004 1125 1133
18. T. Hayasaki, K. Kaikita, and T. Okuma CC chemokine receptor-2 deficiency attenuates oxidative stress and infarct size caused by myocardial ischemia-reperfusion in mice Circ J 70 2006 342 351
19. O. Dewald, P. Zymek, and K. Winkelmann CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts Circ Res 96 2005 881 889
20. N.G. Frangogiannis, O. Dewald, and Y. Xia Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy Circulation 115 2007 584 592
21. L. Zhou, A. Azfer, and J. Niu MCP-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction Circ Res 98 2006 1177 1185
22. E. Lutgens, B. Faber, and K. Schapira Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody Circulation 111 2005 3443 3452
23. A.M. Piccinini, K. Knebl, A. Rek, G. Wildner, M. Diedrichs-Mohring, and A.J. Kungl Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo J Biol Chem 285 2010 8782 8792
24. R.R. Koenen, P. von Hundelshausen, and I.V. Nesmelova Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice Nat Med 15 2009 97 103
25. C. Laguri, R. Sadir, and P. Rueda The novel CXCL12gamma isoform encodes an unstructured cationic domain which regulates bioactivity and interaction with both glycosaminoglycans and CXCR4 PLoS ONE 2 2007 e1110
26. R.R. Koenen, J. Pruessmeyer, and O. Soehnlein Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases Blood 113 2009 4799 4809
27. E.A. Liehn, A. Schober, and C. Weber Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice Arterioscler Thromb Vasc Biol 24 2004 1891 1896
28. U. Zeiffer, A. Schober, and M. Lietz Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines Circ Res 94 2004 776 784
29. C. Weber, M. Aepfelbacher, H. Haag, H.W. Ziegler-Heitbrock, and P.C. Weber Tumor necrosis factor induces enhanced responses to platelet-activating factor and differentiation in human monocytic Mono Mac 6 cells Eur J Immunol 23 1993 852 859
30. E.A. Liehn, M.W. Merx, and O. Postea Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction J Cell Mol Med 12 2008 496 506
31. S. Hemmerich, C. Paavola, and A. Bloom Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2 Biochemistry 38 1999 13013 13025
32. Y. Sun, and K.T. Weber Infarct scar: a dynamic tissue Cardiovasc Res 46 2000 250 256
33. R.R. Koenen, and C. Weber Therapeutic targeting of chemokine interactions in atherosclerosis Nat Rev Drug Discov 9 2010 141 153
34. S. Ali, A.C. Palmer, B. Banerjee, S.J. Fritchley, and J.A. Kirby Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans J Biol Chem 275 2000 11721 11727
35. V. Braunersreuther, S. Steffens, and C. Arnaud A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice Arterioscler Thromb Vasc Biol 28 2008 1090 1096
36. T. Kohno, T. Anzai, and K. Naito Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling Circ J 72 2008 1685 1692
37. J.J. Haringman, D.M. Gerlag, and T.J. Smeets A randomized controlled trial with an anti-CCL2 (anti-MCP-1) monoclonal antibody in patients with rheumatoid arthritis Arthritis Rheum 54 2006 2387 2392
38. M. Buntinx, B. Hermans, and J. Goossens Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3- dihydro-1 H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2 J Pharmacol Exp Ther 327 2008 1 9
39. R. Horuk Chemokine receptor antagonists: overcoming developmental hurdles Nat Rev Drug Discov 8 2009 23 33
40. A. Rek, E. Krenn, and A. Kungl Therapeutically targeting protein-glycan interactions Br J Pharmacol 157 2009 686 694
41. B. Brandner, A. Rek, M. Diedrichs-Mohring, G. Wildner, and A.J. Kungl Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists Protein Eng Des Sel 22 2009 367 373
42. K.L. Hokeness, W.A. Kuziel, C.A. Biron, and T.P. Salazar-Mather MCP-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver J Immunol 174 2005 1549 1556
43. P.M. Robben, M. LaRegina, W.A. Kuziel, and L.D. Sibley Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis J Exp Med 201 2005 1761 1769
44. H. Potzinger, E. Geretti, and B. Brandner Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs Biochem Soc Trans 34 2006 435 437